Late effects in high‐risk neuroblastoma survivors treated with high‐dose chemotherapy and stem cell rescue
- 27 August 2018
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 66 (1) , e27421
Abstract
Background: Current treatment strategies have improved the outcome of high‐risk neuroblastoma (HRNB) at the cost of increasing acute and late effects of treatment. Although high‐dose chemotherapy with stem cell rescue (HDC‐SCR) has replaced total body irradiation (TBI) based HRNB therapy, late effects of therapy remain a significant concern.Objectives: To describe late effects prevalence, severity, and risks after HDC‐SCR.Methods: Retrospective chart review of relapse‐free HRNB survivors ≥1 year after single HDC‐SCR between 2000 and 2015 at Fred Hutchinson Cancer Research Center.Results: Sixty‐one survivors (30 males) were eligible. Median age (years) at SCR was 3.5 years (range 0.7‐27 years) and median posttransplant follow‐up was 5.4 years (1.2‐16.3 years) . Fifty‐three (86.9%) survivors developed late effects that increased over time (P < 0.001) and varied in severity from grade 1 (35) to grade 5 (1). These were unrelated to gender or age. High‐frequency hearing loss seen in 82% of survivors was the most common abnormality present and 43% of those required hearing aids. Seventeen (27.9%) survivors developed dental late effects and these were most common in children P = 0.008). Other toxicities included endocrine (18%), orthopedic (14.8 %), renal (3.9%), melanotic nevi (8.2%), neuropsychological impairments (8.2%), subsequent malignancies (4.9%), pulmonary (4.9%), cardiac (4.9%), and focal nodular liver hyperplasia (3.3%). At 9 years posttransplant, the median height and weight Z‐scores were significantly lower than Z‐scores at the time of HDC‐SCR (–0.01/–1.08, P < 0.001; –0.14/–0.78, P = 0.005).Conclusion: Avoidance of TBI does not mitigate the need to provide diligent, ongoing surveillance for late effects.Keywords
This publication has 22 references indexed in Scilit:
- Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trialThe Lancet Oncology, 2013
- Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group StudyJournal of Clinical Oncology, 2011
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for NeuroblastomaNew England Journal of Medicine, 2010
- Practical Grading System for Evaluating Cisplatin Ototoxicity in ChildrenJournal of Clinical Oncology, 2010
- Long-term Outcomes in Survivors of Neuroblastoma: A Report From the Childhood Cancer Survivor StudyJNCI: Journal of the National Cancer Institute, 2009
- The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force ReportJournal of Clinical Oncology, 2009
- Late effects in survivors of tandem peripheral blood stem cell transplant for high‐risk neuroblastomaPediatric Blood & Cancer, 2008
- Development of Risk-Based Guidelines for Pediatric Cancer Survivors: The Children's Oncology Group Long-Term Follow-Up Guidelines From the Children's Oncology Group Late Effects Committee and Nursing DisciplineJournal of Clinical Oncology, 2004
- Ototoxicity following pediatric hematopoietic stem cell transplantation: A prospective cohort studyPediatric Blood & Cancer, 2004
- Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic AcidNew England Journal of Medicine, 1999